Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Brett Hauber, John R Penrod, David Gebben & Lina Musallam. (2020) The Value of Hope: Patients’ and Physicians’ Preferences for Survival in Advanced Non-Small Cell Lung Cancer. Patient Preference and Adherence 14, pages 2093-2104.
Read now
Read now
Juan Marcos González, Sarika Ogale, Robert Morlock, Joshua Posner, Brett Hauber, Nicolas Sommer & Axel Grothey. (2017) Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Management and Research 9, pages 149-158.
Read now
Read now
Katie D Stewart, Joseph A Johnston, Louis S Matza, Sarah E Curtis, Henry A Havel, Stephanie A Sweetana & Heather L Gelhorn. (2016) Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence 10, pages 1385-1399.
Read now
Read now
Carol Mansfield, Sandy Srinivas, Connie Chen, A. Brett Hauber, Subramanian Hariharan, Ewa Matczak & Rickard Sandin. (2016) The effect of information on preferences for treatments of metastatic renal cell carcinoma. Current Medical Research and Opinion 32:11, pages 1827-1838.
Read now
Read now
Articles from other publishers (27)
Ruilin Ding, Rong Shao, Lingli Zhang & Jianzhou Yan. (2023) Preferences and Willingness to Pay for Medication in Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment. The Patient - Patient-Centered Outcomes Research.
Crossref
Crossref
Shan Jiang, Ru Ren, Yuanyuan Gu, Varinder Jeet, Ping Liu & Shunping Li. (2022) Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments. PharmacoEconomics 41:1, pages 43-57.
Crossref
Crossref
Ovidio Fernández, Martín Lázaro-Quintela, Guillermo Crespo, Diego Soto de Prado, Álvaro Pinto, Laura Basterretxea, Alfonso Gómez de Liaño, Olatz Etxaniz, Sara Blasco, Clara Gabás-Rivera, Susana Aceituno, Virginia Palomar & Carlos Polanco-Sánchez. (2022) Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists. Frontiers in Oncology 11.
Crossref
Crossref
Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins & David F. McDermott. (2021) Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical Cancer Research 27:24, pages 6687-6695.
Crossref
Crossref
Brittany M. Chapman, Jui-Chen Yang, Juan Marcos Gonzalez, Laura Havrilesky, Shelby D. Reed & E. Shelley Hwang. (2021) Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. JCO Oncology Practice 17:11, pages e1639-e1648.
Crossref
Crossref
Hannah Collacott, Vikas Soekhai, Caitlin Thomas, Anne Brooks, Ella Brookes, Rachel Lo, Sarah Mulnick & Sebastian Heidenreich. (2021) A Systematic Review of Discrete Choice Experiments in Oncology Treatments. The Patient - Patient-Centered Outcomes Research 14:6, pages 775-790.
Crossref
Crossref
Sandy Srinivas, Ateesha F. Mohamed, Sreevalsa Appukkuttan, Marc Botteman, Xinyi Ng, Namita Joshi, Erica Horodniceanu, A. Reginald Waldeck & Stacey J Simmons. (2020) Physician preferences for non-metastatic castration-resistant prostate cancer treatment. BMC Urology 20:1.
Crossref
Crossref
Michael J. Raphael, Andrew Robinson, Christopher M. Booth, Jennifer O’Donnell, Michael Palmer, Elizabeth Eisenhauer & Michael Brundage. (2019) The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer. JAMA Oncology 5:12, pages 1779.
Crossref
Crossref
Pengxiang Li, Jordan Jahnke, Amy R. Pettit, Yu-Ning Wong & Jalpa A. Doshi. (2019) Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2:6, pages e195806.
Crossref
Crossref
Jun Guo, Jie Jin, Mototsugu Oya, Hirotsugu Uemura, Shunji Takahashi, Katsunori Tatsugami, Sun Young Rha, Jae-Lyun Lee, Jinsoo Chung, Ho Yeong Lim, Hsi Chin Wu, Yen Hwa Chang, Arun Azad, Ian D. Davis, Marlene J. Carrasco-Alfonso, Bhupinder Nanua, Jackie Han, Qasim Ahmad & Robert Motzer. (2018) Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. Journal of Hematology & Oncology 11:1.
Crossref
Crossref
Juan Marcos González, Justin Doan, David J. Gebben, Marco Boeri & Mayer Fishman. (2018) Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment. PharmacoEconomics 36:8, pages 973-986.
Crossref
Crossref
Eric JonaschRebecca S. SlackDaniel M. GeynismanElshad HasanovMatthew I. MilowskyW. Kimryn RathmellSummer StovallDonna JuarezTroy R. GilchristLisa PruittMoshe C. OrnsteinElizabeth R. PlimackNizar M. TannirBrian I. Rini. (2018) Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology 36:16, pages 1588-1593.
Crossref
Crossref
Daniela R. Bien, Marion Danner, Vera Vennedey, Daniele Civello, Silvia M. Evers & Mickaël Hiligsmann. (2017) Patients’ Preferences for Outcome, Process and Cost Attributes in Cancer Treatment: A Systematic Review of Discrete Choice Experiments. The Patient - Patient-Centered Outcomes Research 10:5, pages 553-565.
Crossref
Crossref
Yuanxi Jia, Hsiaomin Huang & Joel J. Gagnier. (2017) A systematic review of measurement properties of patient-reported outcome measures for use in patients with foot or ankle diseases. Quality of Life Research 26:8, pages 1969-2010.
Crossref
Crossref
Hiroji Uemura, Nobuaki Matsubara, Go Kimura, Akito Yamaguchi, Dianne Athene Ledesma, Marco DiBonaventura, Ateesha F. Mohamed, Enrique Basurto, Ian McKinnon, Ed Wang, Kristen Concialdi, Aya Narimatsu & Yasuko Aitoku. (2016) Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment. BMC Urology 16:1.
Crossref
Crossref
Jennifer L. Beaumont, John M. Salsman, Jose Diaz, Keith C. Deen, Lauren McCann, Thomas Powles, Michelle D. Hackshaw, Robert J. Motzer & David Cella. (2016) Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer 122:7, pages 1108-1115.
Crossref
Crossref
David Cella & Jennifer L. Beaumont. (2015) Pazopanib in the treatment of advanced renal cell carcinoma. Therapeutic Advances in Urology 8:1, pages 61-69.
Crossref
Crossref
Brian P. Hobbs, Peter F. Thall & Steven H. Lin. (2016) Bayesian group sequential clinical trial design using total toxicity burden and progression-free survival. Journal of the Royal Statistical Society: Series C (Applied Statistics) 65:2, pages 273-297.
Crossref
Crossref
Jin‐Shei Lai, Jennifer L. Beaumont, Jose Diaz, Sadya Khan & David Cella. (2015) Validation of a short questionnaire to measure symptoms and functional limitations associated with hand‐foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer 122:2, pages 287-295.
Crossref
Crossref
Carolyn Gotay. (2015) Patient-reported outcomes enhance understanding of the impact of pazopanib in soft tissue sarcoma. Cancer 121:17, pages 2868-2870.
Crossref
Crossref
S. Kalra, B.I. Rini & E. Jonasch. (2015) Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Annals of Oncology 26:7, pages 1300-1304.
Crossref
Crossref
Ateesha F. Mohamed, Juan Marcos González & Angelyn Fairchild. (2015) Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments. Journal of Thyroid Research 2015, pages 1-8.
Crossref
Crossref
Michael D. Clark, Domino Determann, Stavros Petrou, Domenico Moro & Esther W. de Bekker-Grob. (2014) Discrete Choice Experiments in Health Economics: A Review of the Literature. PharmacoEconomics 32:9, pages 883-902.
Crossref
Crossref
George Dranitsaris, Susanne Schmitz & Reuben J. Broom. (2013) Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. Journal of Cancer Research and Clinical Oncology 139:11, pages 1917-1926.
Crossref
Crossref
V Harding, M Afshar, J Krell, R Ramaswami, C J Twelves & J Stebbing. (2013) ‘Being there’ for women with metastatic breast cancer: a pan-European patient survey. British Journal of Cancer 109:6, pages 1543-1548.
Crossref
Crossref
Robert J. Motzer, Thomas E. Hutson, David Cella, James Reeves, Robert Hawkins, Jun Guo, Paul Nathan, Michael Staehler, Paul de Souza, Jaime R. Merchan, Ekaterini Boleti, Kate Fife, Jie Jin, Robert Jones, Hirotsugu Uemura, Ugo De Giorgi, Ulrika Harmenberg, Jinwan Wang, Cora N. Sternberg, Keith Deen, Lauren McCann, Michelle D. Hackshaw, Rocco Crescenzo, Lini N. Pandite & Toni K. Choueiri. (2013) Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine 369:8, pages 722-731.
Crossref
Crossref
A. Brett Hauber, Angelyn O. Fairchild & F. Reed Johnson. (2013) Quantifying Benefit–Risk Preferences for Medical Interventions: An Overview of a Growing Empirical Literature. Applied Health Economics and Health Policy 11:4, pages 319-329.
Crossref
Crossref